Martek Biosciences Corp

Martek Biosciences — Citigroup Healthy Lifestyles Seminar 2008

21 slides from Martek Biosciences's conference presentation, Sep 16, 2008

  1. Slide 1: Martek Biosciences Investor Presentation

    Slide 1: Martek Biosciences Investor Presentation

    Martek Biosciences Investor Presentation Citigroup Healthy Lifestyles Seminar September 2008

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Sections of this presentation contain forward-looking statements concerning, among other things, expectations regarding future revenue growth, product introductions, production expansion, capital expenditures and gross margins. These statements are based upon numerous assumptions that Martek cannot

  3. Slide 3: Martek Biosciences

    Slide 3: Martek Biosciences

    Martek discovers, develops and manufactures proprietary innovative products that improve human health and well-being through nutrition. Martek Biosciences

  4. Slide 4: Company Overview

    Slide 4: Company Overview

    A leading producer of patented nutritional oils including DHA omega-3 and ARA omega-6 DHA + ARA - important for brain and eye development in infants Martek is the global leader in providing DHA omega-3 and ARA omega-6 for use in infant formula DHA - a long-chain omega-3 fatty acid = a "good fat" Exp

  5. Slide 5: Why we need DHA

    Slide 5: Why we need DHA

    Why we need DHA Numerous clinical studies and scientific research confirm that DHA is an important nutrient for brain, eye and heart health throughout life DHA is 97% of the omega-3 fats in the brain DHA is 93% of the omega-3 fats in the retina DHA is a key component of the heart Despite the benefit

  6. Slide 6: DHA is Important Throughout Life

    Slide 6: DHA is Important Throughout Life

    DHA is Important Throughout Life Pregnancy Maternal Health & Outcomes Promotes maternal DHA status Increases DHA content of breast milk Promotes fetal brain and eye development Infants & Children Brain & Eye Development and Function Improves visual acuity Promotes cognitive performance Children & Ad

  7. Slide 7: DHA research on brain and heart health

    Slide 7: DHA research on brain and heart health

    Brain Higher DHA levels are associated with improved listening comprehension and vocabulary skills in preschool children. (Clinical Pediatrics, May 2008) DHA increases levels of a specific protein (LR11) which decreases beta amyloid accumulation in the brain and may play an important role in prevent

  8. Slide 8: 2008 Focus Areas

    Slide 8: 2008 Focus Areas

    Increasing revenue Growing infant formula, primarily outside the U.S. Further expanding DHA sales in non-infant formula markets Building the life'sDHA(tm) brand Signing DHA supply agreements Gaining broader distribution of supplements containing life'sDHA(tm) Increase product launches by growing con

  9. Slide 9: Infant Formula Market

    Slide 9: Infant Formula Market

    28 licensees representing approximately 70% of the worldwide market 95%+ penetration of U.S. market (U.S. = $170m-$190m market opportunity) # of U.S. births has trended up in recent years, with 2007 hitting an all-time high (4.3 million births), slightly surpassing previous highs set during the "bab

  10. Slide 10: Broadening the Use of DHA Nutrition Beyond Infant Formula

    Slide 10: Broadening the Use of DHA Nutrition Beyond Infant Formula

    Broadening the Use of DHA Nutrition Beyond Infant Formula Prenatal vitamins and supplements Supplements for the general population Food and beverage products Animal food and feeds Initial consumers targeted have been moms and their children, baby boomers, and other health conscious consumers Pharmac

  11. Slide 11: Perinatal Products and Supplements

    Slide 11: Perinatal Products and Supplements

    Perinatal Products and Supplements Prescription prenatal vitamins Dietary Supplements OTC prenatal vitamins Recent product launches in CVS and Walgreen's (#1 and #2 pharmacy chains)

  12. Slide 12: Food and Beverage Market Development Strategy

    Slide 12: Food and Beverage Market Development Strategy

    Replicate the successful infant formula market development strategy Establish long-term partnerships with the market leaders Use of Martek logo on product packaging Leverage the branding and marketing expertise of partners to: Develop the life'sDHA(tm) brand Educate consumers / build awareness of th

  13. Slide 13: Key Product Launches - Food & Beverage

    Slide 13: Key Product Launches - Food & Beverage

    Key Product Launches - Food & Beverage 2008 (YTD) 2007 2006 Stella cake Just Launched!

  14. Slide 14: Food & Beverage Category Expansion

    Slide 14: Food & Beverage Category Expansion

    Food & Beverage Category Expansion 2008 2007 2006 Soy beverages Yogurt / yogurt drinks Soy beverages Yogurt / yogurt drinks Fluid milk Fruit juice Baby food Sushi Nutrition bar Chocolate bar Meat Cheese sauce Soy beverages Yogurt / yogurt drinks Fluid milk Fruit juice Baby food Sushi Nutrition bar C

  15. Slide 15: Animal Nutrition

    Slide 15: Animal Nutrition

    Animal Nutrition Expanding the use of DHA in two distinct market segments: 1) animal nutrition (e.g. feeds for swine, poultry, & equine) and 2) companion animals (e.g. pet foods for cats & dogs) October 2007 - signed a global distribution agreement with U.S.- based Novus International, a $700 millio

  16. Slide 16: Why Martek's life'sDHA?

    Slide 16: Why Martek's life'sDHA?

    Higher price than fish oil, but: Sustainability Vegetarian Source (Universal Appeal) Relative Ease of Formulation Real and Perceived Risks of Fish Oil High Quality and Martek's comprehensive array of resources made available to partners in support of developing and marketing products fortified with

  17. Slide 17: New Products In Development

    Slide 17: New Products In Development

    Lower cost delivery forms of DHA DHA food and beverage applications DHA in plants Collaboration agreement for DHA-rich canola oil signed May 2008 with Dow AgroSciences Other high-value products that provide health benefits through nutrition High potency DHA for potential pharmaceutical applications

  18. Slide 18: Production Capabilities

    Slide 18: Production Capabilities

    Two Manufacturing Sites Kingstree, SC and Winchester, KY Dual-plant production capacity Capable of both DHA and ARA production Both plants rated "Superior" by AIB FDA inspected DSM - ARA production partner Plants in Capua, Italy and Belvidere, NJ Multinational fine chemical / fermentation company In

  19. Slide 19: Non-Infant Formula Revenue Trend

    Slide 19: Non-Infant Formula Revenue Trend

    Non-Infant Formula Revenue Trend $11.5 $22.9 $31- $33 *Company guidance provided 09/04/08. Non-Infant Formula nutritional revenue expecting growth in all segments vs. FY'07 ~40% growth vs. FY'07*

  20. Slide 20: Annual Financial Performance + FY'08 Guidance

    Slide 20: Annual Financial Performance + FY'08 Guidance

    FY'04 FY'05 FY'06 FY'07 FY'08E Gross Margin 0.377 0.388 0.36 0.37 0.41 Gross Margin Revenue ($ millions) Gross Margin Non-GAAP EPS* *Excludes restructuring charges, tax gain $349-$353 $1.06- $1.09 Annual Financial Performance + FY'08 Guidance* Infant formula Y/Y growth of 12-13%, up vs. prior guidan

  21. Slide 21: Summary

    Slide 21: Summary

    The global leader in DHA and ARA for infant formula Science in support of lifetime health benefits of DHA continues to grow International growth opportunities in infant formula, and DHA gaining traction in food and beverage, perinatal products and supplements markets Existing assets/infrastructure c

Source: SEC EDGAR · 8-K filed Sep 16, 2008

More decks from Martek Biosciences Corp